Zentalis Pharmaceuticals Inc ZNTL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/14/24 EDT
11.67UNCH (UNCH)
Volume
16,604
Close
11.67UNCH (UNCH)
Volume
488,103
52 week range
9.56 - 31.46
Loading...
  • Open12.04
  • Day High12.68
  • Day Low11.52
  • Prev Close11.75
  • 52 Week High31.46
  • 52 Week High Date05/30/23
  • 52 Week Low9.56
  • 52 Week Low Date11/08/23

Key Stats

  • Market Cap828.724M
  • Shares Out71.01M
  • 10 Day Average Volume0.66M
  • Dividend-
  • Dividend Yield-
  • Beta1.83
  • YTD % Change-22.97

KEY STATS

  • Open12.04
  • Day High12.68
  • Day Low11.52
  • Prev Close11.75
  • 52 Week High31.46
  • 52 Week High Date05/30/23
  • 52 Week Low9.56
  • 52 Week Low Date11/08/23
  • Market Cap828.724M
  • Shares Out71.01M
  • 10 Day Average Volume0.66M
  • Dividend-
  • Dividend Yield-
  • Beta1.83
  • YTD % Change-22.97

RATIOS/PROFITABILITY

  • EPS (TTM)-3.36
  • P/E (TTM)-3.48
  • Fwd P/E (NTM)-3.27
  • EBITDA (TTM)-258.281M
  • ROE (TTM)-67.09%
  • Revenue (TTM)40.56M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-506.16%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Zentalis Pharmaceuticals Inc

 

Profile

MORE
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5...
David Johnson
Independent Chairman of the Board
Kimberly Blackwell M.D.
Chief Executive Officer, Director
Cam Gallagher
President, Executive Director
Iris Roth Ph.D.
Chief Operating Officer
Melissa Epperly
Chief Financial Officer, Treasurer
Andrea Paul J.D.
General Counsel, Corporate Secretary
Address
1359 Broadway, Suite 801
New York, NY
10018
United States

Top Peers

SYMBOLLASTCHG%CHG
RLAY
Relay Therapeutics Inc
6.36UNCHUNCH
BCYC
Bicycle Therapeutics PLC
21.85UNCHUNCH
IMTX
Immatics NV
11.60UNCHUNCH
TNGX
Tango Therapeutics Inc
7.60UNCHUNCH
LQDA
Liquidia Corp
11.96UNCHUNCH